MedTrace Logo

Individual Patient Esmethadone (REL-1017) Expanded Access Program

NCT06009003 · Status: TEMPORARILY_NOT_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2024-08-06

No results posted yet for this study

Summary

To provide expanded access of esmethadone (REL-1017) to patients with a serious or immediately life-threatening disease or condition that may potentially benefit from esmethadone (REL-1017) who do not have access to other effective therapy and are not eligible for other clinical trials with esmethadone (REL-1017).

Conditions

Interventions

DRUG

REL-1017

REL-1017 tablet

Sponsors & Collaborators

  • Sponsor-Investigator

    collaborator UNKNOWN

  • Relmada Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Marco Pappagallo, MD · Relmada Therapeutics

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06009003 on ClinicalTrials.gov